Goldfarb Gross Seligman & Co. has broad exposure to the life sciences and healthcare industry, having maintained a key role in large M&A transactions, among them a $671m going private transaction for a major pharmaceutical company, as well as handling complex regulatory and licensing matters. Head of life sciences Hili Cohen is a key adviser to technology-based companies in the life sciences, medical devices, pharmaceuticals, digital health, telemedicine, diagnostics, and medical cannabis sectors. Corporate and commercial partner Danny Kleinhendler, emerging talent Shir Shalev, and Ofir Goldstein, who handles technology licensing agreements, investments, capital, and development agreements, are the standout practitioners in a diverse, multidisciplinary team.
Legal 500 redaktioneller Kommentar
- Profil
Kernmandanten
- 3 Millenium Group
- Abbott Laboratories
- Accelmed
- Acthera Therapeutics Ltd.
- Agada Medical Ltd.
- AISAP
- AIVF
- Align Technology, Ltd
- Almeda Ventures Limited Partnership
- American Well
Highlight-Mandate
Representing medical device company Magenta Medical in its USD105m Series E financing round.
- Representing the Special Committee of the Board of Directors of Taro Pharmaceutical Industries Ltd. in its USD671m going private transaction by merger with its controlling shareholder, SUN PHARMA Pharmaceutical Industries Limited.
- Representing Israeli biomed company CartiHeal in its acquisition by international medical device company Smith+Nephew plc for up to USD330m, the largest "exit" in the Israeli biomed field in 2023.
Anwält*innen
Führende Partner*innen
Die stärksten Partner*innen ihres Praxisbereichs, die eine führende Rolle in signifikanten Mandaten einnehmen und weitreichende Anerkennung unter Wettbewerbern und Mandanten genießen.
Führende Associates
Führende Associates sind regelmäßig an zentralen Mandaten des Teams beteiligt und erhalten positives Feedback von Wettbewerbern oder Mandanten.
Praxisleitung
Hili Cohen
Weitere Kernanwält*innen
Ofir Goldstein; Shir Shalev; Danny Kleinhendler